Vazquez-Villegas ML, et al. - A retrospective cohort study is carried out to assess incidence and factors related to the development of permanent work disability (PWD) in rheumatoid arthritis (RA) treated with combination therapy utilizing conventional synthetic cs-DMARDs. After the diagnosis of RA, approx 25% of workers with combination therapy with cs-DMARDs developed PWD in 10 years. Some factors increase the risk of disability. Permanent work disability generates a relevant society burden and increases health care costs. Therefore, indicators predicting failure of combination therapies with cs-DMARDs might provide clinicians of helpful tools for modifying treatments avoiding the disease progression.